Case Details
- Citation: [2019] SGHC 231
- Title: Merck KGaA and another v Merck Sharp & Dohme Corp and others
- Court: High Court of the Republic of Singapore
- Date: 30 September 2019
- Judges: Lee Seiu Kin J
- Coram: Lee Seiu Kin J
- Case Number: Suit No 415 of 2018 (Summons 4434 of 2018)
- Procedural Posture: Application for summary judgment and determination of a question of law under O 14 r 12 of the Rules of Court (Cap 322, R5, 2014 Rev Ed)
- Plaintiff/Applicant: Merck KGaA and another
- Defendant/Respondent: Merck Sharp & Dohme Corp and others
- Counsel for Plaintiffs: Alban Kang, Tan Lijun and Mok Ho Fai (Bird & Bird ATMD LLP)
- Counsel for Defendants: Melanie Ho and Jenny Chang (Wong Partnership LLP)
- Collective Parties (as described): Merck KGaA — Merck Pte Ltd — Merck Sharp & Dohme Corp — MSD Pharma (Singapore) Pte Ltd — MSD International GmBh (Singapore Branch) — Merck & Co., Inc
- Legal Areas: Civil Procedure — Judgments and orders; Civil Procedure — Summary Judgment; Issue Estoppel
- Statutes Referenced: German Trade Mark Act; German Unfair Competition Act
- Key Procedural Rule Referenced: O 14 r 12 of the Rules of Court (Cap 322, R5, 2014 Rev Ed) (“ROC”)
- English Decisions Relied On: Merck KGaA v Merck Sharp & Dohme Corp & Others [2014] EWHC 3867 (Ch) (“UK Preliminary Decision”); Merck KGaA v Merck Sharp and Dohme Corp [2016] EWHC 49 (Pat) (“2016 UK Decision”); Merck KGaA v Merck Sharp & Dohme Corp & Ors [2017] EWCA Civ 1834 (“UKCA decision”)
- Foreign Decisions Adduced: Two decisions of the Hamburg court (“Hamburg decisions”)
- Judgment Length: 8 pages, 4,198 words
Summary
In Merck KGaA and another v Merck Sharp & Dohme Corp and others [2019] SGHC 231, the High Court (Lee Seiu Kin J) addressed whether prior English litigation could give rise to issue estoppel in Singapore proceedings concerning a long-running pharmaceutical “Merck” brand co-existence arrangement. The plaintiffs, Merck KGaA and Merck Pte Ltd, sought summary judgment for breach of contract based on a 1970 agreement and a 1975 letter between E.Merck and MSD’s predecessor. Their case depended heavily on the effect of three English decisions culminating in the Court of Appeal’s decision in 2017.
The court’s central task was to determine, as a question of law under O 14 r 12 ROC, whether the English decisions were capable of producing issue estoppels on two points: (i) the governing law of the 1970 agreement and 1975 letter, and (ii) the interpretation of clause 7 of the 1970 agreement. Applying the established requirements for issue estoppel per Thoday v Thoday and The Sennar (No 2), the judge rejected the defendants’ objections and accepted that the English decisions were made by a court of competent jurisdiction and that the necessary identity and “same issue” elements were satisfied.
Although the excerpt provided truncates the later parts of the judgment, the reasoning visible in the decision demonstrates a careful, structured approach to issue estoppel in the context of cross-border corporate succession and multi-party litigation. The court also dealt with procedural challenges to the invocation of issue estoppel and the admissibility and relevance of foreign decisions (including Hamburg decisions) to the legal question posed under O 14 r 12.
What Were the Facts of This Case?
The dispute arises from the historical development of the “Merck” pharmaceutical business. The Merck business originated in Germany in 1668 under the name “E.Merck”. In 1889, Merck established a business in the United States and incorporated Merck & Co., Inc, which later became the predecessor company to MSD. Over time, the Merck and MSD entities operated as separate and independent businesses, with Merck primarily in Europe and MSD primarily in North America. Both groups became highly successful pharmaceutical companies, and the “Merck” name became a valuable trademark and goodwill asset.
As the two groups expanded, they entered into various co-existence arrangements intended to regulate their use of the “Merck” name and related marks in different jurisdictions. Among these arrangements were the 1970 Agreement and the 1975 Letter. The plaintiffs’ Singapore claim focuses on alleged breaches of clauses 4 to 9 of the 1970 Agreement, with particular emphasis on clause 7. Clause 7, as described in the judgment, required MSD to cancel existing registrations, withdraw applications, and discontinue use of specified trademarks including “Merck”, “Merck Cross”, and “MerckMerckMerck” in “all other countries” (i.e., jurisdictions outside those reserved for MSD).
Merck commenced legal proceedings against MSD in 2013. In the UK litigation, the High Court held in the UK Preliminary Decision that the governing law of the 1970 Agreement and the 1975 Letter was German law. Subsequently, in the 2016 UK Decision, the court found that MSD was in breach of clause 7. That finding was upheld on appeal in the UKCA decision. The plaintiffs in Singapore relied on these English decisions as giving rise to issue estoppels, arguing that the defendants were precluded from re-litigating (a) the governing law and (b) the interpretation of clause 7.
Procedurally, the Singapore action was brought by Merck KGaA and Merck Pte Ltd against Merck Sharp & Dohme Corp and related entities, including MSD Pharma (Singapore) Pte Ltd, MSD International GmbH (Singapore Branch), and Merck & Co., Inc. The defendants attempted to challenge the plaintiffs’ standing and contractual linkage by disputing whether Merck was the successor company to E.Merck, the original party to the 1970 Agreement. The court also had to address whether the English decisions could be “recognised” or otherwise relied upon for issue estoppel purposes, and whether any public policy, natural justice, or inconsistency concerns could defeat the estoppel.
What Were the Key Legal Issues?
The first key legal issue was whether the English decisions could give rise to issue estoppel in Singapore proceedings. This issue was framed around two specific estoppels: (a) the governing law of the 1970 Agreement and 1975 Letter, and (b) the interpretation of clause 7 of the 1970 Agreement. The court needed to decide whether the conditions for issue estoppel per The Sennar (No 2) were satisfied, including whether the earlier judgments were final and conclusive, whether the parties were sufficiently identical, and whether the issue in Singapore was the same as that decided in England.
The second issue concerned the plaintiffs’ application for summary judgment. Summary judgment is designed to dispose of cases where there is no real prospect of defending the claim and where the plaintiff’s case is sufficiently clear. Here, summary judgment depended on the preclusive effect of issue estoppel: if the English decisions bound the defendants on the governing law and clause 7 interpretation, the contractual breach analysis would likely become straightforward.
The third issue was procedural and concerned the court’s willingness to determine the O 14 r 12 question of law. The plaintiffs applied under O 14 r 12 ROC to determine whether the English decisions give rise to issue estoppels binding on the defendants. The court had to consider whether the application was timely and whether the defendants had an adequate opportunity to address the issue, particularly given that the application was not made within 28 days of the close of pleadings.
How Did the Court Analyse the Issues?
The judge began by setting out the doctrine of issue estoppel as an extension of the public policy underlying cause of action estoppel. Citing Thoday v Thoday and local authority Goh Nellie v Goh Lian Teck, the court emphasised that once a competent court has determined a separate issue between parties, neither party can later assert the opposite in subsequent litigation on a cause of action that depends on the identical condition. This framing is important because it clarifies that issue estoppel is not merely about factual similarity; it is about the legal or factual “condition” that has been determined and which is necessary to the later claim.
Next, the court identified the four conditions for issue estoppel per rem judicatam from The Sennar (No 2): (a) the earlier judgment must be made by a court of competent jurisdiction; (b) it must be final and conclusive and made on the merits; (c) the parties must be identical; and (d) the issue must be the same. The judge noted that there was no dispute as to the legal principles governing these requirements. The analysis therefore focused on applying each condition to the facts of the Singapore case and the English decisions.
On the “competent jurisdiction” requirement, the defendants argued that the plaintiffs had not applied for leave to procedurally “recognise” the English decisions. The judge rejected this submission as lacking authority and logic. The defendants did not argue that they were not amenable to the English courts or that they had not voluntarily submitted. The judge therefore accepted that the English decisions were handed down by a court of competent jurisdiction.
The defendants also attempted to invoke defences akin to those used in recognition and enforcement of foreign judgments, such as public policy and fraud/natural justice concerns. They relied on Humpuss Sea Transport Pte Ltd (in compulsory liquidation) v PT Humpuss Intermoda Transportasi TBK, which discusses circumstances where recognition or enforcement may be refused. The judge found no basis for these defences on the materials before the court. The only relevant point raised was the possibility of inconsistent future decisions in Singapore. The judge treated this as insufficient, particularly because there were no existing local decisions on the subject matter at that time. In other words, the inconsistency concern did not engage the traditional refusal grounds.
The most fact-intensive part of the analysis concerned the identity of parties requirement. The defendants made two arguments: first, that the English proceedings included additional parties not present in Singapore; and second, that Merck was not the successor company to E.Merck, the original contracting party. The judge approached the first argument by recognising that issue estoppel can bind parties who are common to both proceedings even if not all parties in the earlier action are present in the later action. He held that MSD and Merck & Co., Inc were common parties between the UK Preliminary Decision and the Singapore action, and that they could be bound by issue estoppel even if other parties were not present in Singapore. Similarly, MSD and Merck & Co., Inc were common parties to the UKCA decision and could be bound by issues decided there.
On the successor company point, the judge rejected the defendants’ position. The excerpt indicates that there was evidence that MSD had sued Merck in the United States on the same 1970 Agreement, and that the English court in the UKCA decision had held that Merck was the successor to E.Merck. While the remainder of the judgment is truncated in the provided extract, the judge’s approach signals that the court treated the successor issue as one already determined in England, and therefore as a matter that could not be re-litigated if it formed part of the same “condition” necessary for the Singapore contractual claim.
Finally, the court dealt with the procedural mechanics of the O 14 r 12 determination. The plaintiffs’ application was initially made outside the 28-day window after close of pleadings. However, the judge granted leave, taking into account the defendants’ position that they lacked adequate opportunity to address the O 14 r 12 issue. The hearing was adjourned, and the defendants later obtained leave to adduce further evidence in the form of two Hamburg decisions, on the ground that they were relevant to the legal issue under O 14 r 12. This illustrates the court’s balancing of procedural fairness with the efficiency goals of summary judgment and early determination of legal questions.
What Was the Outcome?
The excerpt provided does not include the final orders. However, the structure of the judgment and the judge’s findings on the threshold requirements for issue estoppel indicate that the court was prepared to accept that the English decisions could bind the defendants in Singapore on the governing law and clause 7 interpretation. This would, in turn, strongly support the plaintiffs’ summary judgment application because the contractual breach analysis would be anchored on the precluded issues.
Practically, the outcome of such a decision would be to prevent the defendants from re-arguing German governing law and the meaning of clause 7, thereby narrowing the dispute to the remaining elements of breach and relief. For litigants, the case demonstrates that issue estoppel can operate across jurisdictions where the earlier foreign litigation has already determined the key contractual questions.
Why Does This Case Matter?
This case is significant for Singapore practitioners because it illustrates how issue estoppel can be invoked in Singapore based on English judgments, even where the Singapore proceedings involve related but not identical corporate defendants. The court’s analysis confirms that the “identity of parties” requirement is not applied mechanically. Where parties are common to both proceedings, and where the earlier court has determined the same issue necessary to the later cause of action, issue estoppel can bind parties in Singapore notwithstanding differences in the wider party composition of the earlier litigation.
It also matters because the court addressed procedural objections to the invocation of issue estoppel. The defendants’ argument that a formal “recognition” application was necessary was rejected for lack of authority and for reasons of logic and common sense. This is a useful point for lawyers planning litigation strategy: the ability to rely on foreign judgments for issue estoppel purposes is not necessarily dependent on additional procedural steps, provided the estoppel requirements are met.
From a substantive perspective, the case shows the role of early determination mechanisms (O 14 r 12) in commercial disputes involving complex cross-border facts. By deciding whether issue estoppel applies, the court can potentially dispose of the case or at least narrow it substantially, thereby supporting the efficiency objectives behind summary judgment.
Legislation Referenced
- German Trade Mark Act
- German Unfair Competition Act
- Rules of Court (Cap 322, R5, 2014 Rev Ed), O 14 r 12
Cases Cited
- Thoday v Thoday [1964] P 181
- Goh Nellie v Goh Lian Teck and others [2007] 1 SLR(R) 453
- The Sennar (No 2) [1985] 1 Lloyd’s Rep 521
- Lee Tat Development Pte Ltd v MCST Plan No 301 [2005] 3 SLR(R) 157
- Humpuss Sea Transport Pte Ltd (in compulsory liquidation) v PT Humpuss Intermoda Transportasi TBK and another [2016] 5 SLR 1322
- Merck KGaA v Merck Sharp & Dohme Corp & Others [2014] EWHC 3867 (Ch)
- Merck KGaA v Merck Sharp and Dohme Corp [2016] EWHC 49 (Pat)
- Merck KGaA v Merck Sharp & Dohme Corp & Ors [2017] EWCA Civ 1834
Source Documents
This article analyses [2019] SGHC 231 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the full judgment for the Court's complete reasoning.